This analysis examines the historical and forecast performance for Solvayin the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Solvay's performance against key rivals in the ethical pharmaceutical sector Assess the impact of Solvay's acquisition of Fournier, including the significant expansion of its CV sales force Analyze how the delayed launch of antipsychotic bifeprunox will impact Solvay's commercial performance over 2006-12.